JP2010515742A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010515742A5 JP2010515742A5 JP2009545652A JP2009545652A JP2010515742A5 JP 2010515742 A5 JP2010515742 A5 JP 2010515742A5 JP 2009545652 A JP2009545652 A JP 2009545652A JP 2009545652 A JP2009545652 A JP 2009545652A JP 2010515742 A5 JP2010515742 A5 JP 2010515742A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- antibody
- item
- buffer
- months
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 121
- 238000009472 formulation Methods 0.000 claims description 105
- 238000002360 preparation method Methods 0.000 claims description 27
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 22
- 239000000872 buffer Substances 0.000 claims description 19
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 16
- 229930006000 Sucrose Natural products 0.000 claims description 14
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 239000005720 sucrose Substances 0.000 claims description 14
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 12
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 12
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 12
- 208000006673 asthma Diseases 0.000 claims description 12
- 239000011780 sodium chloride Substances 0.000 claims description 12
- 239000004475 Arginine Substances 0.000 claims description 8
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 8
- 239000004471 Glycine Substances 0.000 claims description 8
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 8
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 8
- 239000002577 cryoprotective agent Substances 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 229930182817 methionine Natural products 0.000 claims description 8
- 229920000136 polysorbate Polymers 0.000 claims description 8
- 239000000600 sorbitol Substances 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 239000000443 aerosol Substances 0.000 claims description 6
- 238000007710 freezing Methods 0.000 claims description 6
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 6
- 238000007912 intraperitoneal administration Methods 0.000 claims description 6
- 239000012931 lyophilized formulation Substances 0.000 claims description 6
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 6
- 229920000053 polysorbate 80 Polymers 0.000 claims description 6
- 239000004094 surface-active agent Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 4
- 239000008351 acetate buffer Substances 0.000 claims description 4
- 201000009961 allergic asthma Diseases 0.000 claims description 4
- 229940125369 inhaled corticosteroids Drugs 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 201000010659 intrinsic asthma Diseases 0.000 claims description 4
- 229940125386 long-acting bronchodilator Drugs 0.000 claims description 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 4
- 229940068968 polysorbate 80 Drugs 0.000 claims description 4
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 claims description 4
- 239000008362 succinate buffer Substances 0.000 claims description 4
- 206010003557 Asthma exercise induced Diseases 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 208000004657 Exercise-Induced Asthma Diseases 0.000 claims description 2
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 208000001132 Osteoporosis Diseases 0.000 claims description 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 2
- 229920001219 Polysorbate 40 Polymers 0.000 claims description 2
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 2
- 229920002642 Polysorbate 65 Polymers 0.000 claims description 2
- 229920002651 Polysorbate 85 Polymers 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 208000000491 Tendinopathy Diseases 0.000 claims description 2
- 206010043255 Tendonitis Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 230000000172 allergic effect Effects 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 229940125715 antihistaminic agent Drugs 0.000 claims description 2
- 239000000739 antihistaminic agent Substances 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 238000003556 assay Methods 0.000 claims description 2
- 238000004166 bioassay Methods 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 239000008121 dextrose Substances 0.000 claims description 2
- 239000002270 dispersing agent Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 208000024695 exercise-induced bronchoconstriction Diseases 0.000 claims description 2
- 230000004761 fibrosis Effects 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 239000011521 glass Substances 0.000 claims description 2
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims description 2
- 238000011577 humanized mouse model Methods 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000007913 intrathecal administration Methods 0.000 claims description 2
- 238000007914 intraventricular administration Methods 0.000 claims description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 2
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000012669 liquid formulation Substances 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 208000007892 occupational asthma Diseases 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 2
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 claims description 2
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 claims description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims description 2
- 239000001816 polyoxyethylene sorbitan tristearate Substances 0.000 claims description 2
- 235000010988 polyoxyethylene sorbitan tristearate Nutrition 0.000 claims description 2
- 229940068977 polysorbate 20 Drugs 0.000 claims description 2
- 229940101027 polysorbate 40 Drugs 0.000 claims description 2
- 229940113124 polysorbate 60 Drugs 0.000 claims description 2
- 229940099511 polysorbate 65 Drugs 0.000 claims description 2
- 229940113171 polysorbate 85 Drugs 0.000 claims description 2
- 238000000159 protein binding assay Methods 0.000 claims description 2
- 230000017702 response to host Effects 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 201000004409 schistosomiasis Diseases 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 201000004415 tendinitis Diseases 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 239000007853 buffer solution Substances 0.000 claims 3
- 229910052571 earthenware Inorganic materials 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 210000001179 synovial fluid Anatomy 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87950007P | 2007-01-09 | 2007-01-09 | |
| US60/879,500 | 2007-01-09 | ||
| PCT/US2008/050582 WO2008086395A2 (en) | 2007-01-09 | 2008-01-09 | Anti-il-13 antibody formulations and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010515742A JP2010515742A (ja) | 2010-05-13 |
| JP2010515742A5 true JP2010515742A5 (cg-RX-API-DMAC7.html) | 2012-02-02 |
| JP5419709B2 JP5419709B2 (ja) | 2014-02-19 |
Family
ID=39609351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009545652A Expired - Fee Related JP5419709B2 (ja) | 2007-01-09 | 2008-01-09 | 抗ｉｌ−１３抗体製剤およびその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20090060906A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2114451A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5419709B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN101600457B (cg-RX-API-DMAC7.html) |
| AR (1) | AR064826A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2008204901A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0806313A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2674608A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2008000058A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2009007406A (cg-RX-API-DMAC7.html) |
| PE (1) | PE20081610A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW200837080A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008086395A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (112)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8703126B2 (en) | 2000-10-12 | 2014-04-22 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
| US9415102B2 (en) | 2002-09-06 | 2016-08-16 | Alexion Pharmaceuticals, Inc. | High concentration formulations of anti-C5 antibodies |
| US20050271660A1 (en) * | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
| NZ538384A (en) * | 2002-09-06 | 2009-04-30 | Alexion Pharma Inc | Treatment for asthma using a compound which binds to or otherwise blocks the generation and/or activity of one or more complement components reptors, such as, C5a receptors |
| BRPI0403964B8 (pt) | 2003-04-04 | 2021-05-25 | Genentech Inc | formulações líquidas estáveis, artigo manufaturado e uso dessas formulações para o tratamento de disfunção mediada por ige |
| KR101531400B1 (ko) | 2003-06-27 | 2015-06-26 | 암젠 프레몬트 인코포레이티드 | 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그용도 |
| EP2083861A4 (en) | 2006-11-07 | 2010-11-24 | Merck Sharp & Dohme | ANTAGONISTS OF PCSK9 |
| JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
| PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| AR070315A1 (es) * | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Anticuerpos 1b20 antagonistas de pcsk9 |
| AR070316A1 (es) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9) |
| PT2993186T (pt) | 2008-03-14 | 2019-11-29 | Biocon Ltd | Anticorpo monoclonal e um método do mesmo |
| TW201022288A (en) | 2008-06-30 | 2010-06-16 | Novo Nordisk As | Anti-human interleukin-20 antibodies |
| US20120034212A1 (en) * | 2009-01-29 | 2012-02-09 | Michael Bowen | Human Anti-IL-6 Antibodies With Extended In Vivo Half-Life And Their Use In Treatment Of Oncology, Autoimmune Diseases And Inflammatory Diseases |
| AU2010221156A1 (en) * | 2009-03-06 | 2011-09-22 | Genentech, Inc. | Antibody formulation |
| GB0904214D0 (en) | 2009-03-11 | 2009-04-22 | Ucb Pharma Sa | Biological products |
| WO2010128265A2 (fr) * | 2009-05-07 | 2010-11-11 | Stallergenes S.A. | Utilisation d'immunoglobulines igg1 et/ou de ligands du récepteur cd32 pour le traitement de maladies et manifestations inflammatoires par voie mucosale |
| US8454956B2 (en) | 2009-08-31 | 2013-06-04 | National Cheng Kung University | Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies |
| CN102770157B (zh) * | 2009-11-20 | 2017-05-17 | 拜康有限公司 | 抗体的配制品 |
| US8765432B2 (en) | 2009-12-18 | 2014-07-01 | Oligasis, Llc | Targeted drug phosphorylcholine polymer conjugates |
| TWI505838B (zh) | 2010-01-20 | 2015-11-01 | Chugai Pharmaceutical Co Ltd | Stabilized antibody solution containing |
| PT2533761T (pt) * | 2010-02-11 | 2019-06-17 | Ablynx Nv | Métodos e composições para a preparação de aerossóis |
| EP3216462A3 (en) | 2010-02-26 | 2017-12-20 | Novo Nordisk A/S | Stable antibody containing compositions |
| WO2011134979A2 (en) | 2010-04-27 | 2011-11-03 | Scil Technology Gmbh | Stable mia/cd-rap formulation |
| RU2012153786A (ru) * | 2010-05-28 | 2014-07-10 | Ново Нордиск А/С | Стабильные многодозовые композиции, содержащие антитело и консервант |
| JP6126532B2 (ja) | 2010-11-04 | 2017-05-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗ｉｌ−２３抗体 |
| EP2652498B1 (en) | 2010-12-16 | 2018-04-18 | F.Hoffmann-La Roche Ag | Diagnosis and treatments relating to th2 inhibition |
| TWI719112B (zh) | 2011-03-16 | 2021-02-21 | 賽諾菲公司 | 雙重ｖ區類抗體蛋白質之用途 |
| DK2691112T3 (en) | 2011-03-31 | 2018-07-30 | Merck Sharp & Dohme | STABLE FORMULATIONS OF ANTIBODIES AGAINST HUMAN PD (PROGRAMMED DEATH) 1- RECEPTOR AND RELATED TREATMENTS |
| JOP20200043A1 (ar) * | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| UY34105A (es) * | 2011-06-03 | 2012-07-31 | Lg Life Sciences Ltd | Formulación líquida estable de etanercept |
| CN103857411A (zh) * | 2011-07-13 | 2014-06-11 | 阿布维公司 | 使用抗il-13抗体治疗哮喘的方法和组合物 |
| WO2013012022A1 (ja) | 2011-07-19 | 2013-01-24 | 中外製薬株式会社 | アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤 |
| SI3091029T1 (sl) * | 2011-10-31 | 2023-03-31 | F. Hoffmann - La Roche Ag | Pripravki protiteles proti IL13 |
| MX368653B (es) * | 2012-05-03 | 2019-10-10 | Boehringer Ingelheim Int | Anticuerpos anti-il-23p19. |
| SG11201407779YA (en) * | 2012-06-21 | 2015-02-27 | Ucb Pharma Sa | Pharmaceutical formulation |
| US9221904B2 (en) | 2012-07-19 | 2015-12-29 | National Cheng Kung University | Treatment of osteoarthritis using IL-20 antagonists |
| US8603470B1 (en) | 2012-08-07 | 2013-12-10 | National Cheng Kung University | Use of IL-20 antagonists for treating liver diseases |
| US8852588B2 (en) | 2012-08-07 | 2014-10-07 | National Cheng Kung University | Treating allergic airway disorders using anti-IL-20 receptor antibodies |
| UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
| TWI679019B (zh) * | 2013-04-29 | 2019-12-11 | 法商賽諾菲公司 | 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物 |
| EP3738613A1 (en) | 2013-07-23 | 2020-11-18 | Biocon Limited | Use of a cd6 binding partner and method based thereon |
| WO2015035342A2 (en) | 2013-09-08 | 2015-03-12 | Oligasis Llc | Factor viii zwitterionic polymer conjugates |
| NZ718144A (en) | 2013-09-13 | 2022-05-27 | Genentech Inc | Methods and compositions comprising purified recombinant polypeptides |
| WO2015038884A2 (en) | 2013-09-13 | 2015-03-19 | Genentech, Inc. | Compositions and methods for detecting and quantifying host cell protein in cell lines and recombinant polypeptide products |
| CA2924873A1 (en) | 2013-10-23 | 2015-04-30 | Genentech, Inc. | Methods of diagnosing and treating eosinophilic disorders |
| US9045545B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision medicine by targeting PD-L1 variants for treatment of cancer |
| US8980273B1 (en) | 2014-07-15 | 2015-03-17 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
| US9023359B1 (en) | 2014-07-15 | 2015-05-05 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
| US8992927B1 (en) | 2014-07-15 | 2015-03-31 | Kymab Limited | Targeting human NAV1.7 variants for treatment of pain |
| US9914769B2 (en) | 2014-07-15 | 2018-03-13 | Kymab Limited | Precision medicine for cholesterol treatment |
| US8986694B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Targeting human nav1.7 variants for treatment of pain |
| US9067998B1 (en) | 2014-07-15 | 2015-06-30 | Kymab Limited | Targeting PD-1 variants for treatment of cancer |
| US9051378B1 (en) | 2014-07-15 | 2015-06-09 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
| US8986691B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
| US8883157B1 (en) | 2013-12-17 | 2014-11-11 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
| US9034332B1 (en) | 2014-07-15 | 2015-05-19 | Kymab Limited | Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment |
| US9045548B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment |
| US9017678B1 (en) | 2014-07-15 | 2015-04-28 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
| IL310015B1 (en) | 2013-12-31 | 2025-10-01 | Access To Advanced Health Inst | Single vial formulation |
| EP3107574A2 (en) | 2014-02-21 | 2016-12-28 | F. Hoffmann-La Roche AG | Anti-il-13/il-17 bispecific antibodies and uses thereof |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| US9139648B1 (en) | 2014-07-15 | 2015-09-22 | Kymab Limited | Precision medicine by targeting human NAV1.9 variants for treatment of pain |
| US9150660B1 (en) | 2014-07-15 | 2015-10-06 | Kymab Limited | Precision Medicine by targeting human NAV1.8 variants for treatment of pain |
| WO2016014775A1 (en) | 2014-07-24 | 2016-01-28 | Boehringer Ingelheim International Gmbh | Biomarkers useful in the treatment of il-23a related diseases |
| MX388301B (es) | 2014-09-03 | 2025-03-19 | Boehringer Ingelheim Int | Il-23a y tnf-alfa orientados y compuesto y sus usos. |
| WO2016061562A2 (en) | 2014-10-17 | 2016-04-21 | Kodiak Sciences Inc. | Butyrylcholinesterase zwitterionic polymer conjugates |
| MA55068A (fr) | 2014-10-24 | 2022-01-05 | Merck Sharp & Dohme | Co-agonistes des récepteurs du glucagon et du glp-1 |
| MA41115A (fr) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| JP2018500380A (ja) * | 2014-12-31 | 2018-01-11 | ノベルメド セラピューティクス，インコーポレーテッド | アグリコシル化治療用抗体の製剤 |
| WO2016126638A1 (en) | 2015-02-04 | 2016-08-11 | Boehringer Ingelheim International Gmbh | Methods of treating inflammatory diseases |
| HK1247287A1 (zh) | 2015-03-16 | 2018-09-21 | F. Hoffmann-La Roche Ag | 检测和定量il-13的方法和在诊断和治疗th2相关疾病中的用途 |
| AR104847A1 (es) * | 2015-06-17 | 2017-08-16 | Lilly Co Eli | Formulación de anticuerpo anti-cgrp |
| KR101808234B1 (ko) | 2015-06-23 | 2017-12-12 | (주)알테오젠 | IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제 |
| EP3383435A4 (en) * | 2015-11-30 | 2019-07-10 | Medimmune, LLC | OPTIMIZED RATES OF AMINO ACIDS AND SUGARS AS AMORPHOUS STABILIZING COMPOUNDS IN PHARMACEUTICAL COMPOSITIONS HAVING HIGH CONCENTRATIONS IN PROTEIN-BASED THERAPEUTICS |
| JP7088454B2 (ja) | 2015-12-30 | 2022-06-21 | コディアック サイエンシーズ インコーポレイテッド | 抗体および抗体複合体 |
| HUE067896T2 (hu) | 2016-04-27 | 2024-11-28 | Abbvie Mfg Management Unlimited Company | Olyan betegségek kezelési módszerei az anti-IL-13 antitestek alkalmazásával, amelyekben az IL-13 aktivitás káros |
| CN116903741A (zh) | 2016-06-20 | 2023-10-20 | 科马布有限公司 | 特异性结合于pd-l1的抗体或其抗原结合片段及其用途 |
| NZ790629A (en) | 2016-09-23 | 2025-11-28 | Genentech Inc | Uses of il-13 antagonists for treating atopic dermatitis |
| US11242401B2 (en) | 2016-10-21 | 2022-02-08 | Biocon Limited | Monoclonal antibody and a method of use for the treatment of lupus |
| WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| TW202444416A (zh) | 2017-02-01 | 2024-11-16 | 耶魯大學 | 心臟衰竭及心腎症候群之精準治療 |
| MX2019010282A (es) * | 2017-03-01 | 2020-01-09 | Medimmune Ltd | Formulacion de anticuerpos monoclonales. |
| CA3059938A1 (en) | 2017-04-14 | 2018-10-18 | Kodiak Sciences Inc. | Complement factor d antagonist antibodies and conjugates thereof |
| WO2018200533A1 (en) | 2017-04-28 | 2018-11-01 | Amgen Inc. | Excipients to reduce the viscosity of antibody formulations and formulation compositions |
| CA3060581A1 (en) | 2017-05-02 | 2018-11-08 | Merck Sharp & Dohme Corp. | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies |
| JOP20190260A1 (ar) * | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| RU2749342C1 (ru) | 2017-07-25 | 2021-06-08 | Цзянсу Хэнжуй Медицин Ко., Лтд. | Фармацевтическая композиция на основе белкового комплекса il-15 и ее применения |
| MA49947B1 (fr) * | 2017-08-22 | 2023-03-31 | Biogen Ma Inc | Compositions pharmaceutiques contenant des anticorps anti-bêta-amyloïdes |
| WO2019040608A1 (en) * | 2017-08-22 | 2019-02-28 | Biogen Ma Inc. | PHARMACEUTICAL COMPOSITIONS AND DOSAGE SCHEMES CONTAINING ANTI-ALPHA (V) BETA ANTIBODIES (6) |
| WO2019136312A1 (en) | 2018-01-05 | 2019-07-11 | Corvidia Therapeutics, Inc. | Methods for treating il-6 mediated inflammation without immunosuppression |
| KR102417088B1 (ko) | 2018-02-09 | 2022-07-07 | 제넨테크, 인크. | 비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법 |
| CN112203679A (zh) | 2018-03-02 | 2021-01-08 | 科达制药股份有限公司 | Il-6抗体及其融合构建体和缀合物 |
| EP3801469A4 (en) * | 2018-06-07 | 2022-03-09 | Merck Sharp & Dohme Corp. | CRITICAL LYOSPHERE REAGENTS KIT |
| TW202011995A (zh) * | 2018-07-03 | 2020-04-01 | 比利時商葛萊伯格有限公司 | 高濃度液體抗體配製物 |
| WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
| MX2021005394A (es) | 2018-11-07 | 2021-07-06 | Merck Sharp & Dohme Llc | Co-formulaciones de anticuerpos anti-gen de activacion de linfocitos 3 (anti-lag3) y anticuerpos anti-muerte programada-1 (anti-pd-1). |
| MA55033A (fr) | 2019-02-18 | 2021-12-29 | Lilly Co Eli | Formulation d'anticorps thérapeutique |
| CN109771398B (zh) * | 2019-02-25 | 2019-09-20 | 广州南鑫药业有限公司 | 一种帕拉米韦溶液型吸入剂及其制备方法 |
| JOP20220030A1 (ar) * | 2019-08-16 | 2023-01-30 | Regeneron Pharma | صيغ مضادة لـ c5 عالية التركيز |
| WO2021072265A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| CA3161504A1 (en) * | 2019-12-20 | 2021-06-24 | Chiara IORIO | Igg:tgf.beta.rii fusion protein composition |
| JP2023512286A (ja) * | 2020-01-31 | 2023-03-24 | サノフイ | 抗体の肺送達 |
| GB2595299B (en) | 2020-05-21 | 2022-08-03 | Mabsolve Ltd | Modified immunoglobulin FC regions |
| EP4272756A4 (en) * | 2021-02-05 | 2024-12-11 | Bio-Thera Solutions, Ltd. | ANTI-IL-5 ANTIBODY FORMULATION, MANUFACTURING METHOD AND USE THEREOF |
| AU2022345969A1 (en) | 2021-09-15 | 2024-03-07 | Dermira, Inc. | Il-13 inhibitors for the treatment of prurigo nodularis |
| WO2024165671A1 (en) | 2023-02-08 | 2024-08-15 | Immunos Therapeutics Ag | FUSION PROTEINS OF ß2 MICROGLOBULIN, HLA HEAVY CHAIN POLYPEPTIDES, AND INHIBITOR OF CD47-SIRPA |
| WO2025128984A1 (en) | 2023-12-14 | 2025-06-19 | Dermira, Inc. | Il-13 antibodies for the treatment of chronic rhinosinusitis with nasal polyps |
| WO2025128990A1 (en) | 2023-12-14 | 2025-06-19 | Dermira, Inc. | Il-13 antibodies for the treatment of perennial allergic rhinitis |
| WO2025184453A1 (en) | 2024-03-01 | 2025-09-04 | Dermira, Inc. | Il-13 antibodies for the treatment of post-inflammatory hyperpigmentation or hypopigmentation of skin |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6685940B2 (en) * | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| DK1516628T3 (da) * | 1995-07-27 | 2013-09-08 | Genentech Inc | Stabil, isotonisk lyofiliseret proteinformulering |
| US6171586B1 (en) * | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| EP0999853B1 (en) * | 1997-06-13 | 2003-01-02 | Genentech, Inc. | Stabilized antibody formulation |
| ATE442862T2 (de) * | 2000-10-12 | 2009-10-15 | Genentech Inc | Niederviskose konzentrierte proteinformulierungen |
| DE60235013D1 (de) * | 2001-07-25 | 2010-02-25 | Facet Biotech Corp | Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab |
| ATE414537T1 (de) * | 2001-08-29 | 2008-12-15 | Chugai Pharmaceutical Co Ltd | Antikörper enthaltende stabilisierte zubereitungen |
| US20040248260A1 (en) * | 2001-10-26 | 2004-12-09 | Heavner George A. | IL-13 mutein proteins, antibodies, compositions, methods and uses |
| US20040191243A1 (en) * | 2002-12-13 | 2004-09-30 | Bei Chen | System and method for stabilizing antibodies with histidine |
| DK2236154T3 (en) * | 2003-02-10 | 2018-06-25 | Biogen Ma Inc | IMMUNOGLOBULIN INFORMATION AND METHOD OF PREPARING IT |
| US7501121B2 (en) * | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
| AR049390A1 (es) * | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
| US20070048785A1 (en) * | 2004-06-09 | 2007-03-01 | Lin Laura L | Anti-IL-13 antibodies and complexes |
| CA2623429C (en) * | 2005-09-30 | 2015-01-13 | Medimmune Limited | Interleukin-13 antibody composition |
| BRPI0618893A2 (pt) * | 2005-11-22 | 2011-09-13 | Wyeth Corp | formulações de proteìna de fusão de imunoglobulina |
| TW200806317A (en) * | 2006-03-20 | 2008-02-01 | Wyeth Corp | Methods for reducing protein aggregation |
-
2008
- 2008-01-09 AU AU2008204901A patent/AU2008204901A1/en not_active Abandoned
- 2008-01-09 WO PCT/US2008/050582 patent/WO2008086395A2/en not_active Ceased
- 2008-01-09 JP JP2009545652A patent/JP5419709B2/ja not_active Expired - Fee Related
- 2008-01-09 PE PE2008000098A patent/PE20081610A1/es not_active Application Discontinuation
- 2008-01-09 CL CL200800058A patent/CL2008000058A1/es unknown
- 2008-01-09 CN CN200880001927.XA patent/CN101600457B/zh not_active Expired - Fee Related
- 2008-01-09 AR ARP080100083A patent/AR064826A1/es unknown
- 2008-01-09 US US12/008,129 patent/US20090060906A1/en not_active Abandoned
- 2008-01-09 MX MX2009007406A patent/MX2009007406A/es active IP Right Grant
- 2008-01-09 EP EP08713660A patent/EP2114451A2/en not_active Withdrawn
- 2008-01-09 BR BRPI0806313-3A patent/BRPI0806313A2/pt active Search and Examination
- 2008-01-09 TW TW097100809A patent/TW200837080A/zh unknown
- 2008-01-09 CA CA002674608A patent/CA2674608A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010515742A5 (cg-RX-API-DMAC7.html) | ||
| JP7286595B2 (ja) | 抗体製剤 | |
| JP5419709B2 (ja) | 抗ｉｌ−１３抗体製剤およびその使用 | |
| Church et al. | Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders | |
| JP2023060016A (ja) | モノクローナル抗体製剤 | |
| JP4879884B2 (ja) | 抗−ｉｌ−９抗体製剤及びその使用法 | |
| JP2010500360A5 (cg-RX-API-DMAC7.html) | ||
| ES2936387T3 (es) | Formulaciones de anticuerpos anti-il13 | |
| JP2008528638A5 (cg-RX-API-DMAC7.html) | ||
| JP5605895B2 (ja) | Ｃｏｐｄを処置するためのｃｄ２０結合分子 | |
| RU2017131618A (ru) | Стабильный жидкий состав для моноклональных антител | |
| US20140227250A1 (en) | Stable formulations of antibodies to tslp | |
| RU2640025C2 (ru) | Способы и композиции для лечения астмы с использованием антител против il-13 | |
| RU2007124933A (ru) | Стабилизированные жидкие полипептидные составы | |
| CN102458469A (zh) | 人抗TNF-α抗体的稳定高蛋白质浓度制剂 | |
| JP2017535285A5 (cg-RX-API-DMAC7.html) | ||
| JP2016540761A (ja) | 変形性関節症を治療するための組成物及び方法 | |
| US20250269020A1 (en) | Stable formulations of anti-ilt4 antibodies or antigen-binding fragments thererof in combination with anti-pd-1 antibodies and methods of use thereof | |
| CN116406290A (zh) | 用于治疗慢性炎症性疼痛的抗il-36r抗体 | |
| JP2023524866A (ja) | 抗ｉｌ－３３抗体の処方物 | |
| JP2024510923A (ja) | 汎発性膿疱性乾癬を処置する方法 | |
| JPWO2019186369A5 (cg-RX-API-DMAC7.html) | ||
| AU2014201308A1 (en) | Anti-IL-13 antibody formulations and uses thereof | |
| CA3250813A1 (en) | PHARMACEUTICAL FORMULATIONS OF AN ANTI-ILT4 ANTIBODY OR AN ANTIGEN-BINDING FRAGMENT OF IT AND METHODS OF USE | |
| JPWO2023079086A5 (cg-RX-API-DMAC7.html) |